LaNova Medicines, founded in 2019, is a research-driven biotech company specializing in the discovery and development of antibody-based cancer treatments. The company operates in the oncology sector, targeting both the Chinese and global markets. LaNova's business model revolves around leveraging its proprietary platforms and distinctive development strategies to create a robust pipeline of differentiated programs. These programs are driven forward into clinical stages with unmatched speed and efficiency, setting industry standards. LaNova serves patients with various types of cancer, including pancreatic, gastric, and gastroesophageal junction cancers. The company generates revenue through licensing agreements, such as the one with Turning Point Therapeutics for LM 302, and through funding rounds, like the Series B financing closed in June 2022. LaNova's seasoned management team brings decades of leadership experience in multinational pharmaceutical and local biotech organizations, providing a unique perspective on both the Chinese market and the global arena.

Keywords: antibody-based, cancer treatments, GPCRs, multi-transmembrane proteins, oncology, clinical stages, proprietary platforms, licensing agreements, biotech, innovation.